Adagio Therapeutics to Participate in Upcoming Investor Conferences
Hedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%
Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Adagio's COVID-19 Antibody Meets Primary Goals Across Pre & Post-Exposure Prophylaxis, Treatment
Why Adagio Therapeutics Stock Is Soaring Today
Why Adagio Therapeutics Stock Is Soaring Today
Adagio Stock Spikes on New Data, but Its Omicron Problems Remain
Trading Penny Stocks? Top Stock Market News for March 30th, 2022
2 Net Current Asset Value Stocks to Consider
Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention
12 biotech stocks to consider buying now as prospects for the sector brighten this year
Top 5 IPOs of 2021
Why Shares of Adagio Therapeutics Soared 25.9% on Thursday
5 Top Biotech Stocks To Watch In January 2022
Adagio Therapeutics Stock (ADGI): Why The Price Went Up Today
Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Why Adagio Therapeutics Stock Dived by 13% Today
Adagio Therapeutics Stock (ADGI): Why The Price Surged Over 120% Today
ADGI Stock Alert: 4 Things to Know as Adagio Therapeutics Rockets 100%
What's Going On With Adagio Therapeutics Stock Today?
Why Adagio Therapeutics Stock Is Falling Again Today
ADGI Stock Alert: The Omicron Variant Just Sent Adagio Therapeutics Plunging
Why Are Adagio Shares Plunging Today?
Will Adagio's COVID Antibody Therapy Be Too Late to the Party?
Adagio Therapeutics stock outlook as shares spike 35% on social media chatter
Adagio Therapeutics extends 3-day gain to 319% on hopes that its antiviral can treat the Omicron variant
ADGI Stock: The Social Media Chatter That Has Adagio Therapeutics Soaring Today
Morgan Stanley: Omicron will benefit this relatively new biotech firm
4 Top Biotech Stocks To Watch Now
ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential
Adagio Therapeutics (ADGI) Stock: Why The Price Surged Today
Adagio Therapeutics to Participate in Upcoming Investor Conferences
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results
Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial
3 Biotech Stocks That Soared to New Heights Last Week
DoubleDown Interactive Makes Its Market Debut, Wrapping Up a Slow Month for IPOs
U.S. IPO Weekly Recap: Postponements Abound In A 4 IPO Week
Adagio Therapeutics' upsized IPO prices in middle of range, valued company at more than $1.8 billion